Rowland Laura M, Bustillo Juan R, Mullins Paul G, Jung Rex E, Lenroot Rhoshel, Landgraf Elma, Barrow Ranee, Yeo Ronald, Lauriello John, Brooks William M
Department of Psychiatry, MIND Imaging Center, University of New Mexico, USA.
Am J Psychiatry. 2005 Feb;162(2):394-6. doi: 10.1176/appi.ajp.162.2.394.
The authors' goal was to test in humans the hypothesis that N-methyl-d-aspartate receptor (NMDAR) antagonism results in increased cortical glutamate activity, as proposed by the NMDAR hypofunction model of schizophrenia.
4-T 1H proton magnetic resonance spectroscopy (1H-MRS) was used to acquire in vivo spectra from the bilateral anterior cingulate of 10 healthy subjects while they received a subanesthetic dose of either placebo or ketamine, an NMDAR antagonist. Assessments given before and after ketamine or placebo administration included the Brief Rating Psychiatric Rating Scale, the Scale for the Assessment of Negative Symptoms, the Clinician-Administered Dissociative States Scale, and the Stroop task.
As predicted, there was a significant increase in anterior cingulate glutamine, a putative marker of glutamate neurotransmitter release, with ketamine administration. This increase was not related to schizophrenia-like positive or negative symptoms but was marginally related to Stroop performance.
In humans as in animals, an acute hypofunctional NMDAR state is associated with increased glutamatergic activity in the anterior cingulate.
作者的目标是在人体中检验如下假设,即如精神分裂症的N-甲基-D-天冬氨酸受体(NMDAR)功能减退模型所提出的,NMDAR拮抗作用会导致皮质谷氨酸活性增加。
使用4-T 1H质子磁共振波谱(1H-MRS)在10名健康受试者接受亚麻醉剂量的安慰剂或NMDAR拮抗剂氯胺酮时,从其双侧前扣带回采集体内波谱。在氯胺酮或安慰剂给药前后进行的评估包括简明精神病评定量表、阴性症状评定量表、临床医生实施的分离状态量表和斯特鲁普任务。
如预期的那样,给予氯胺酮后,前扣带回谷氨酰胺(一种假定的谷氨酸神经递质释放标志物)显著增加。这种增加与精神分裂症样的阳性或阴性症状无关,但与斯特鲁普任务表现略有相关。
与动物一样,在人体中,急性NMDAR功能减退状态与前扣带回谷氨酸能活性增加有关。